The Role of Sevista in the Management of Dysfunctional Uterine Bleeding

BS, Dhananjay

doi:10.7860/jcdr/2012/4794.2687

Cited by 15 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results suggested that there is a significant increase in Hb level ( P < 0.0001) and decrease in ET ( P < 0.0001) as because ormeloxifene has anti-proliferative effect on endometrium which causes endometrial atrophy leading to decrease in menstrual blood loss. Our study is in accordance with Bs and Nanda[11] and also with Kriplani et al .,[9] where they have found a significant rise in Hb level and decrease in ET. Grover et al .…”

Section: Discussionsupporting

confidence: 93%

Ormeloxifene–Looking beyond contraception

Pati¹,

Chanania²,

Marandi³

et al. 2017

J Mid-life Health

View full text Add to dashboard Cite

Aims:This study is aimed at finding out a logical solution for perimenopausal menorrhagia in normal or bulky uterus.Settings and Design:The study is carried out at a tertiary care hospital at Odisha. In our setup, nearly 900 hysterectomies are done per year out of which 60% are for menorrhagia with bulky uterus.Subjects and Methods:There were sixty cases of menorrhagia between the ages of 40 and 55 years who completed child bearing treated with ormeloxifene. Their endometrial thickness (ET) and hemoglobin (Hb) level were determined at the start of the study and also at 6 months and compared. At 1 year from the start of treatment, patients' satisfaction and status of menstrual cycle were reassessed.Statistical Analysis Used:Age and parity variables were expressed as mean ± standard deviation and range. We used the paired samples t-test to estimate the mean, median, range, P and t value. All statistical analyses were performed using SPSS software version 11.5 (IBM Corp) and tests of statistical significance were two-sided and differences were taken as significant when P < 0.05.Results:After 1 year of follow-up, 90% of patients found to be amenorrhoic and only two out of them presented with mild irritability and vasomotor complaints which resolved with counseling and placebo therapy. There was a significant reduction (P < 0.0001) in ET and rise in Hb level (P < 0.0001).Conclusions:Ormeloxifene is a safe drug which can be used to treatment of perimenopausal bleeding with minimal focal pathology.

show abstract

Section: Discussionsupporting

confidence: 93%

Ormeloxifene–Looking beyond contraception

Pati¹,

Chanania²,

Marandi³

et al. 2017

J Mid-life Health

View full text Add to dashboard Cite

show abstract

“…Similar to the present study, Dhananjay et al found a statistically significant increase in hemoglobin concentration (8.26 to 10.59g/dl; p<0.001) and a statistically significant decrease in the endometrial thickness (8.36 to 4.89mm; p<0.001) after 3 months of treatment with ormeloxifene [8].…”

Section: Discussionsupporting

confidence: 90%

“…Amenorrhea was a common symptom seen in different studies with a wide range of 8% to 42.9% [3][4][5]8,9]. It is more common in perimenopausal women However, with proper counseling the women do not find it bothersome, in fact it is welcomed by them.…”

Section: Discussionmentioning

confidence: 99%

The Efficacy and Safety of Ormeloxifene in Dysfunctional Uterine Bleeding

Agarwal¹

2013

IOSR-JPBS

View full text Add to dashboard Cite

“…Present study shows ET reduction of 3.33 mm in control group while 2.44 mm in study group, which is comparable with other studies. [10][11][12][13][14] Our data shows comparable results for reduction of endometrial thickness in both control group as well as study group and also comparable with other studies. It proves that 30mg of ormeloxifene is as effective as 60mg of ormeloxifene in treatment of DUB when effectiveness of treatment assessed in form of reduction of endometrial thickness.…”

Section: Discussionsupporting

confidence: 79%

“…(8.26 to 10.59gm%; p<0.001). 12 In a study by Biswas et al mean rise in hemoglobin after treatment was 1.31gm% (9.42 to 10.73gm%; p<0.001). 11 In a study by Neha et al mean rise in hemoglobin was 2.88gm% (7.52 to 10.4gm%).…”

Section: Discussionmentioning

confidence: 99%

Comparative study to evaluate efficacy of 30 mg of ormeloxifene to 60 mg of ormeloxifene in cases of dysfunctional uterine bleeding

Dhakne¹,

Gupta²

2016

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Dysfunctional uterine bleeding is most common menstrual disorder. Third generation selective estrogen receptor modulator ormeloxifene is relatively recent modality of treatment for this condition. Conventionally ormeloxifene in dose of 60 mg is used to treat this condition. In this study 30 mg of ormeloxifene was used for treatment of DUB and its efficacy was compared with 60 mg dose. Objective was to evaluate whether 30 mg of ormeloxifene will be as efficacious as 60mg of ormeloxifene in the treatment of dysfunctional uterine bleeding. Methods: In this study patients presenting to the outpatient department or emergency with clinical features suggestive of dysfunctional uterine bleeding were included. Random number table was used and 60 patients assigned in two groups with 30 patients in each group. Study group and control group patients were administered T. ormeloxifene 30 mg and 60 mg respectively. Both groups received it twice week for 12 weeks and weekly for next 12 weeks. Patients followed up 4 weekly and efficacy of treatment assessed in terms of decrease pictorial blood assessment chart (PBAC) score, rise in hemoglobin and reduction in endometrial thickness. Results: Treatment efficacy in terms of hemoglobin rise, decrease in PBAC score and reduction in endometrial thickness was assessed and it was found that ormeloxifene in dose of 30 mg as well as in 60 mg was equally efficacious. Conclusions: Patients treated with 30mg dose of ormeloxifene showed efficacy of treatment comparable to 60 mg dose. Patients receiving 30 mg dose showed significant increase in mean hemoglobin, significant fall in mean endometrial thickness and also significant reduction in menstrual blood loss. 30 mg can be used as the optimum dose for the treatment of DUB with similar efficacy of treatment and more cost effectiveness.

show abstract

The Role of Sevista in the Management of Dysfunctional Uterine Bleeding

Cited by 15 publications

References 9 publications

Ormeloxifene–Looking beyond contraception

Ormeloxifene–Looking beyond contraception

The Efficacy and Safety of Ormeloxifene in Dysfunctional Uterine Bleeding

Comparative study to evaluate efficacy of 30 mg of ormeloxifene to 60 mg of ormeloxifene in cases of dysfunctional uterine bleeding

Contact Info

Product

Resources

About